Epstein Secrets

e AP (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug

Igor Kostyukov, head of the Main Directorate of the General Staff of the Russian Armed Forces, and Dmitry Badin, a military intelligence officer." Badin is "also being sought by U.S. authorities." An EU statement said, "This cyber-attack targeted the parliament's information system and affected its

63> (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average — in a large study led by the U.S. National Institutes of Health." The drug

Igor Kostyukov, head of the Main Directorate of the General Staff of the Russian Armed Forces, and Dmitry Badin, a military intelligence officer." Badin is "also being sought by U.S. authorities." An EU statement said, "This cyber-attack targeted the parliament's information system and affected its o

e AP (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug

Igor Kostyukov, head of the Main Directorate of the General Staff of the Russian Armed Forces, and Dmitry Badin, a military intelligence officer." Badin is "also being sought by U.S. authorities." An EU statement said, "This cyber-attack targeted the parliament's information system and affected its